{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:04:28Z","timestamp":1782968668968,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die Mastozytose bei Kindern ist eine seltene Erkrankung, die durch eine abnorme Vermehrung von Gewebemastzellen gekennzeichnet ist. Es zeigen sich typische Hautver\u00e4nderungen, die als makulopapul\u00f6se kutane Mastozytose, diffuse kutane Mastozytose oder Mastozytom klassifiziert werden. Ein Teil der Patientinnen und Patienten weist zudem Mastzellmediatorsymptome wie Juckreiz, Flush und Anaphylaxie auf. Bei vielen Kindern ist die Erkrankung durch einen benignen, meist selbstlimitierenden Verlauf charakterisiert; nur selten findet sich eine systemische Mastozytose mit extrakutaner Beteiligung und chronischem oder progressivem Verlauf. Therapeutisch werden in erster Linie H<jats:sub>1<\/jats:sub>-Antihistaminika eingesetzt, je nach Schwere bedarfsorientiert oder als Dauertherapie. Kinder, Eltern und Betreuungspersonen sollten sorgf\u00e4ltig \u00fcber das Krankheitsbild und m\u00f6gliche Trigger-Faktoren der Mastzellmediatorfreisetzung aufgekl\u00e4rt werden. F\u00fcr Kinder mit ausgepr\u00e4gten Hautver\u00e4nderungen und schweren Symptomen ist die Verordnung eines Adrenalin-Autoinjektors zur Notfallbehandlung empfehlenswert.<\/jats:p>","DOI":"10.1007\/s00105-023-05168-9","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T13:02:17Z","timestamp":1683205337000},"page":"323-329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mastozytose bei Kindern","Mastocytosis in children"],"prefix":"10.1007","volume":"74","author":[{"given":"Hanna","family":"Wassmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"key":"5168_CR1","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/j.1398-9995.2012.02812.x","volume":"67","author":"I Alvarez-Twose","year":"2012","unstructured":"Alvarez-Twose\u00a0I, Va\u00f1\u00f3-Galv\u00e1n\u00a0S, S\u00e1nchez-Mu\u00f1oz\u00a0L et al (2012) Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis. Allergy 67:813\u2013821","journal-title":"Allergy"},{"key":"5168_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/modpathol.2013.117","volume":"27","author":"S Berezowska","year":"2014","unstructured":"Berezowska\u00a0S, Flaig\u00a0MJ, Ru\u00ebff\u00a0F et al (2014) Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis. Mod Pathol 27:19\u201329","journal-title":"Mod Pathol"},{"key":"5168_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.iac.2014.01.003","volume":"34","author":"K Brockow","year":"2014","unstructured":"Brockow\u00a0K (2014) Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin North Am 34:283\u2013295","journal-title":"Immunol Allergy Clin North Am"},{"issue":"5","key":"5168_CR4","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.3390\/ijms22052684","volume":"22","author":"K Brockow","year":"2021","unstructured":"Brockow\u00a0K, Plata-Nazar\u00a0K, Lange\u00a0M et al (2021) Mediator-related symptoms and anaphylaxis in children with mastocytosis. Int J Mol Sci 22(5):2684","journal-title":"Int J Mol Sci"},{"key":"5168_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/bjh.15624","volume":"183","author":"MC Carter","year":"2018","unstructured":"Carter\u00a0MC, Bai\u00a0Y, Ruiz-Esteves\u00a0KN et al (2018) Detection of KIT D816V in peripheral blood of children with manifestations of cutaneous mastocytosis suggests systemic disease. Br J Haematol 183:775\u2013782","journal-title":"Br J Haematol"},{"key":"5168_CR6","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.jaci.2015.04.024","volume":"136","author":"MC Carter","year":"2015","unstructured":"Carter\u00a0MC, Clayton\u00a0ST, Komarow\u00a0HD et\u00a0al (2015) Assessment of clinical findings, tryptase levels, and bone marrow histopathology in the management of pediatric mastocytosis. J\u00a0Allergy Clin Immunol 136:1673\u20131679.e3","journal-title":"J Allergy Clin Immunol"},{"key":"5168_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2165\/11588890-000000000-00000","volume":"12","author":"M Castells","year":"2011","unstructured":"Castells\u00a0M, Metcalfe\u00a0DD, Escribano\u00a0L (2011) Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol 12:259\u2013270","journal-title":"Am J Clin Dermatol"},{"key":"5168_CR8","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","volume":"374","author":"J Gotlib","year":"2016","unstructured":"Gotlib\u00a0J, Kluin-Nelemans\u00a0HC, George\u00a0TI et\u00a0al (2016) Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med 374:2530\u20132541","journal-title":"N Engl J Med"},{"key":"5168_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1055\/s-0037-1617781","volume":"3","author":"K Hartmann","year":"2003","unstructured":"Hartmann\u00a0K (2003) Kindliche Mastozytosen. Kinder Jugendmed 3:111\u2013116","journal-title":"Kinder Jugendmed"},{"key":"5168_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","volume":"137","author":"K Hartmann","year":"2016","unstructured":"Hartmann\u00a0K, Escribano\u00a0L, Grattan\u00a0C et\u00a0al (2016) Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J\u00a0Allergy Clin Immunol 137:35\u201345","journal-title":"J Allergy Clin Immunol"},{"key":"5168_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S0889-8588(05)70299-9","volume":"14","author":"K Hartmann","year":"2000","unstructured":"Hartmann\u00a0K, Metcalfe\u00a0DD (2000) Pediatric mastocytosis. Hematol Oncol Clin North Am 14:625\u2013640","journal-title":"Hematol Oncol Clin North Am"},{"key":"5168_CR12","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1053\/j.gastro.2005.06.060","volume":"129","author":"K Hartmann","year":"2005","unstructured":"Hartmann\u00a0K, Wardelmann\u00a0E, Ma\u00a0Y et\u00a0al (2005) Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology 129:1042\u20131046","journal-title":"Gastroenterology"},{"key":"5168_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/MOP.0000000000000922","volume":"32","author":"SH Hussain","year":"2020","unstructured":"Hussain\u00a0SH (2020) Pediatric mastocytosis. Curr Opin Pediatr 32:531\u2013538","journal-title":"Curr Opin Pediatr"},{"key":"5168_CR14","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1016\/j.anai.2022.08.757","volume":"129","author":"I Krase","year":"2022","unstructured":"Krase\u00a0I, Tiano\u00a0R, Varghese\u00a0M et\u00a0al (2022) Infantile aggressive systemic mastocytosis treated with oral midostaurin. Ann Allergy Asthma Immunol 129:S91","journal-title":"Ann Allergy Asthma Immunol"},{"key":"5168_CR15","first-page":"620","volume":"6","author":"M Krystel-Whittemore","year":"2015","unstructured":"Krystel-Whittemore\u00a0M, Dileepan\u00a0KN, Wood\u00a0JG (2015) Mast cell: a multi-functional master cell. Front Immunol 6:620","journal-title":"Front Immunol"},{"key":"5168_CR16","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.3390\/ijms22052586","volume":"22","author":"M Lange","year":"2021","unstructured":"Lange M, Hartmann K, Carter MC et\u00a0al (2021) Molecular background, clinical features and management of pediatric mastocytosis: status 2021. Int J Mol Sci 22:2586","journal-title":"Int J Mol Sci"},{"key":"5168_CR17","doi-asserted-by":"publisher","first-page":"e1906","DOI":"10.1371\/journal.pone.0001906","volume":"3","author":"F Lanternier","year":"2008","unstructured":"Lanternier\u00a0F, Cohen-Akenine\u00a0A, Palmerini\u00a0F et al (2008) Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. Plos One 3:e1906","journal-title":"Plos One"},{"key":"5168_CR18","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1016\/j.jaip.2019.05.032","volume":"7","author":"MM Liu","year":"2019","unstructured":"Liu\u00a0MM, Kohn\u00a0LA, Roach\u00a0GD et\u00a0al (2019) Treatment of systemic mastocytosis in an infant with midostaurin. J\u00a0Allergy Clin Immunol Pract 7:2929\u20132931.e1","journal-title":"J Allergy Clin Immunol Pract"},{"key":"5168_CR19","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bjd.13567","volume":"172","author":"C M\u00e9ni","year":"2015","unstructured":"M\u00e9ni\u00a0C, Bruneau\u00a0J, Georgin-Lavialle\u00a0S et al (2015) Paediatric mastocytosis: a\u00a0systematic review of 1747\u00a0cases. Br J Dermatol 172:642\u2013651","journal-title":"Br J Dermatol"},{"key":"5168_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jpeds.2012.08.035","volume":"162","author":"MA Morren","year":"2013","unstructured":"Morren\u00a0MA, Hopp\u00e9\u00a0A, Renard\u00a0M et\u00a0al (2013) Imatinib mesylate in the treatment of diffuse cutaneous mastocytosis. J Pediatr 162:205\u2013207","journal-title":"J Pediatr"},{"key":"5168_CR21","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1002\/ccr3.1607","volume":"6","author":"IM Otani","year":"2018","unstructured":"Otani\u00a0IM, Carroll\u00a0RW, Yager\u00a0P et\u00a0al (2018) Diffuse cutaneous mastocytosis with novel somatic KIT mutation K509I and association with tuberous sclerosis. Clin Case Rep 6:1834\u20131840","journal-title":"Clin Case Rep"},{"key":"5168_CR22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000059404","volume":"128","author":"WR Sperr","year":"2002","unstructured":"Sperr\u00a0WR, Jordan\u00a0JH, Fiegl\u00a0M et\u00a0al (2002) Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol 128:136\u2013141","journal-title":"Int Arch Allergy Immunol"},{"key":"5168_CR23","doi-asserted-by":"publisher","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","volume":"6","author":"WR Sperr","year":"2019","unstructured":"Sperr\u00a0WR, Kundi\u00a0M, Alvarez-Twose\u00a0I et\u00a0al (2019) International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematol 6:e638\u2013e649","journal-title":"Lancet Haematol"},{"key":"5168_CR24","doi-asserted-by":"publisher","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","volume":"5","author":"P Valent","year":"2021","unstructured":"Valent\u00a0P, Akin\u00a0C, Hartmann\u00a0K et\u00a0al (2021) Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. Hemasphere 5:e646","journal-title":"Hemasphere"},{"key":"5168_CR25","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","volume":"129","author":"P Valent","year":"2017","unstructured":"Valent\u00a0P, Akin\u00a0C, Metcalfe\u00a0DD (2017) Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood 129:1420\u20131427","journal-title":"Blood"},{"key":"5168_CR26","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/ced.12225","volume":"39","author":"HJ Wang","year":"2014","unstructured":"Wang\u00a0HJ, Lin\u00a0ZM, Zhang\u00a0J et\u00a0al (2014) A new germline mutation in KIT associated with diffuse cutaneous mastocytosis in a\u00a0Chinese family. Clin Exp Dermatol 39:146\u2013149","journal-title":"Clin Exp Dermatol"},{"issue":"583","key":"5168_CR27","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.jaci.2015.05.034","volume":"136","author":"T Wiechers","year":"2015","unstructured":"Wiechers\u00a0T, Rabenhorst\u00a0A, Schick\u00a0T et al (2015) Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis. J\u00a0Allergy Clin Immunol 136(583):1581\u20131590.e3","journal-title":"J Allergy Clin Immunol"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-023-05168-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-023-05168-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-023-05168-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T01:23:55Z","timestamp":1683768235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-023-05168-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["5168"],"URL":"https:\/\/doi.org\/10.1007\/s00105-023-05168-9","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"4 May 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.\u00a0Hartmann und H.\u00a0Wassmer geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}